Canine Atopic Dermatitis Market by Product, Allergen, Route of Administration, Distribution Channel, End-User

Description

List of Tables

[190 Pages Report] The Canine Atopic Dermatitis Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.69 billion in 2024, at a CAGR 8.40% to reach USD 2.76 billion by 2030.

Canine atopic dermatitis (CAD) is a chronic, pruritic inflammatory skin condition in dogs due to an inherited predisposition to aberrant immune responses and environmental allergens. Increasing dog ownership rates with changing lifestyles and greater awareness about pet healthcare have led to the adoption of CAD treatments worldwide. Recent years have observed advancements in diagnostic techniques, enabling effective treatment solutions for this chronic condition. However, high costs associated with diagnostics and long-term management can also be a barrier for pet owners, limiting the adoption of new treatments and therapies. Regulatory hurdles can impede the development and approval of novel therapeutics in the canine atopic dermatitis market. Companies are working on innovative research to offer cost-effective treatments while ensuring knowledge of the changing regulations to ensure the commercialization of diverse CAD treatments. Emerging technologies such as next-generation sequencing (NGS) could help identify genetic factors contributing to canine atopic dermatitis susceptibility or treatment response, providing valuable information for personalized therapy approaches.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.57 billion
Estimated Year [2024]	USD 1.69 billion
Forecast Year [2030]	USD 2.76 billion
CAGR (%)	8.40%

Regional Insights

The Americas CAD market is advancing, driven by huge developments in veterinary medicine and ongoing research activities by established companies to offer new-generation treatments. With an increasing number of pet owners becoming aware of CAD's impact on their pets' quality of life in the U.S. and Canada, demand for effective treatments has surged in the region. The prevalence of CAD is significantly rising across Asian countries, particularly in urbanized regions. However, limited awareness about veterinary dermatology and fragmented market structures present challenges to companies catering to this region. Major global players have established a presence in Asia; however they need to contend with smaller local manufacturers that offer cost-effective alternatives for CAD treatments. The European market presents a mature landscape for veterinary dermatology, characterized by well-established companies offering specialized diagnostic tools and therapeutic solutions for managing CAD. Partnerships between leading pharmaceutical firms have led to the development of innovative monoclonal antibody therapies, which offer targeted relief from pruritus associated with atopic dermatitis.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Canine Atopic Dermatitis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing number of pet ownership and rising pollution related to allergens on dogs
- Rising focus on natural ingredients or non-pharmacological methods

Market Restraints
- Increasing use of off-label drugs among pets

Market Opportunities
- Rise in the R&D investments product launches for canine atopic dermatitis (CAD)
- Ongoing demand for pet insurance and rising concerns among pet owners

Market Challenges
- Complex etiology of CAD & concerns over treatment efficacy and safety

Market Segmentation Analysis
- Product: Expanding use of antihistamines and glucocorticoids for effective treatment of CAD
- Allergen: Dust mites and microscopic parasites prevail as the major cause of CAD
- Route of Administration: Injectables and orals to be the most preferred mode of medication application
- Distribution Channel: Emerging availability of CAD medications through online distribution channels
- End-User: Increasing CAD diagnosis in clinics and need for effective treatments

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Canine Atopic Dermatitis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Canine Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Zoetis Opens New State-of-the-Art Facility in Lincoln, NE, USA

Zoetis conducted the opening of its state-of-the-art mAbs expansion facility in Lincoln, Nebraska, and the facility comprises manufacturing, testing, and support buildings, employing a dedicated workforce of nearly 950 employees who work around the clock year-round. The facility is responsible for the production of animal health biologics, biopharmaceuticals, and pharmaceutical products tailoring to meet the specific needs of animals. [Published On: 2023-08-09]

Zoetis Announces FDA Approval of Apoquel Chewable (oclacitinib chewable tablet) for Control of Pruritus Associated With Allergic Dermatitis and Control of Atopic Dermatitis in Dogs

Zoetis Inc. announced that the FDA approved Apoquel chewable tablet for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and above. This chewable treatment is the first of its kind in the U.S., offering comparable efficacy to the original Apoquel (oclacitinib tablet). [Published On: 2023-06-13]

ILC Therapeutics entered into a strategic R&D partnership with Dechra Pharmaceuticals

UK-based biotech company ILC Therapeutics announced a research and development partnership with Dechra Pharmaceuticals. The collaboration aims to develop ILC's Caniferon product to treat canine atopic dermatitis. This collaboration contributes to their existing pipeline and may lead to a full development program and can enable the effective development of an effective treatment for canine atopic dermatitis. [Published On: 2023-05-24]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Canine Atopic Dermatitis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Canine Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, AbbVie, Inc., Agrolabo SpA, Bimeda, Inc., Bioceltix JSC, Bioiberica S.A.U., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Deep Marine Collagen, Elanco Animal Health Incorporated, Farnam Companies, Inc., IDEXX Laboratories, Inc., Incyte Corporation, Kemin Industries, Inc., LEO Pharma A/S, Merck & Co. Inc., Natural Dog Company, Nextmune, Nippon Zenyaku Kogyo Co., Ltd., Novartis AG, Ourofino Animal Health, Pfizer Inc, Phibro Animal Health Corporation, Regeneron Pharmaceuticals, Inc, Saiba Animal Health AG, Toray Industries Inc., Vetoquinol S.A., Virbac Corporation, Zinpro Corporation, Zoetis Inc., and Zymox by Pet King Brands LLC.

Market Segmentation & Coverage

This research report categorizes the Canine Atopic Dermatitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Antihistamines
- Glucocorticoids
- Immunosuppressants
- Monoclonal Antibodies

Allergen
- Dander
- Microorganisms
- Mites
- Pollen

Route of Administration
- Injectable
- Oral
- Topical

Distribution Channel
- Hospitals & Clinics
- Online
- Retail Veterinary

End-User
- Hospitals
- Veternary Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-A339DAEFA20E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing number of pet ownership and rising pollution related to allergens on dogs
  - 5.1.1.2. Rising focus on natural ingredients or non-pharmacological methods
- 5.1.2. Restraints
  - 5.1.2.1. Increasing use of off-label drugs among pets
- 5.1.3. Opportunities
  - 5.1.3.1. Rise in the R&D investments product launches for canine atopic dermatitis (CAD)
  - 5.1.3.2. Ongoing demand for pet insurance and rising concerns among pet owners
- 5.1.4. Challenges
  - 5.1.4.1. Complex etiology of CAD & concerns over treatment efficacy and safety
5.2. Market Segmentation Analysis
- 5.2.1. Product: Expanding use of antihistamines and glucocorticoids for effective treatment of CAD
- 5.2.2. Allergen: Dust mites and microscopic parasites prevail as the major cause of CAD
- 5.2.3. Route of Administration: Injectables and orals to be the most preferred mode of medication application
- 5.2.4. Distribution Channel: Emerging availability of CAD medications through online distribution channels
- 5.2.5. End-User: Increasing CAD diagnosis in clinics and need for effective treatments
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Canine Atopic Dermatitis Market, by Product

6.1. Introduction
6.2. Antihistamines
6.3. Glucocorticoids
6.4. Immunosuppressants
6.5. Monoclonal Antibodies

7. Canine Atopic Dermatitis Market, by Allergen

7.1. Introduction
7.2. Dander
7.3. Microorganisms
7.4. Mites
7.5. Pollen

8. Canine Atopic Dermatitis Market, by Route of Administration

8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical

9. Canine Atopic Dermatitis Market, by Distribution Channel

9.1. Introduction
9.2. Hospitals & Clinics
9.3. Online
9.4. Retail Veterinary

10. Canine Atopic Dermatitis Market, by End-User

10.1. Introduction
10.2. Hospitals
10.3. Veternary Clinics

11. Americas Canine Atopic Dermatitis Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Canine Atopic Dermatitis Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Canine Atopic Dermatitis Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Zoetis Opens New State-of-the-Art Facility in Lincoln, NE, USA
- 14.3.2. Zoetis Announces FDA Approval of Apoquel Chewable (oclacitinib chewable tablet) for Control of Pruritus Associated With Allergic Dermatitis and Control of Atopic Dermatitis in Dogs
- 14.3.3. ILC Therapeutics entered into a strategic R&D partnership with Dechra Pharmaceuticals
- 14.3.4. Bioiberica Launches Dog And Cat Collar For Atopic Dermatitis Featuring Company's Lipids-Based Biosfeen Ingredient
- 14.3.5. Royal Canin North America Announces Launch of SKINTOPIC to Help in the Management of Canine Atopic Dermatitis
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio